Covid 19 Research using Clinical Trials (Home Page)
HP:0000020: Urinary incontinenceHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3019 | Urinary Incontinence Wiki | 1.00 |
| drug2574 | Sedentary behaviour Wiki | 1.00 |
There is one clinical trial.
Clinical Trials
1 Associations Between Urinary Incontinence, Sedentary Behaviour and Other Health-related Outcomes in Nursing Homes in Catalonia: the OsoNaH Project
The increase of the older adult population in the past years has generated an important impact on chronic conditions and geriatric syndromes like dementia, falls and urinary incontinence (UI). To better understand IU seems warranted because of its socioeconomic and health impact. Nursing home (NH) residents are the frailest segment of our population, with very low physical activity levels and highly sedentary. Several studies had shown that physical activity levels and time and patterns of sedentary behaviour (SB) are independent risk factors for many health issues. As far as the investigators know, there is no evidence supporting the relation between IU and SB, and no information about the incidence of IU in NH residents living in Catalonia (Spain). This project consists of two stages: stage 1 will conduct a cross-sectional study using mixed methodology (qualitative and quantitative), and a 2-year longitudinal study (stage 2). Stage 1 has the main objective of verifying the prevalence of IU and its associated factors in NH residents in Barcelona (Spain), as well as analyse the association between IU (and their types) with SB time and patterns. In addition, the proportion of geriatric residents who receive control measures for their IU, and whether they receive SB-related interventions from health professionals of the institution will be also explored. Finally, the investigators aim to understand the experience of NH residents and the health professionals who care for them about the characteristics, burden and barriers of having IU. Stage 2 has the main objective to verify the incidence of the functional and continence decline, falls, hospitalizations and mortality, as well as their predictive factors in older care/nursing home residents in Barcelona (Spain). Specific objetives are to assess the evolution of each activity of daily living and the causes of hospitalization and death in geriatrics residents for a period of 2 years and to verify the incidence of recurrent falls (one or more falls), and analyse the consequences of falls (fractures, hospitalizations, among others) among the residents. Potential risk and protective factors for mortality due to COVID-19 and its impact on functioning and hospitalizations will also be analyzed. Finally, the stage 2 of the project aims at creating a specific instrument for the evaluation of frailty in institutionalized older people, based on the main predictive factors of functional decline.
NCT04297904 Urinary Incontinence in Old Age Sedentary Behavior Behavioral: Sedentary behaviour Diagnostic Test: Urinary Incontinence MeSH:Urinary Incontinence Enuresis
HPO:Enuresis Urinary incontinence
Primary Outcomes
Description: The presence of IU assessed by the Minimum Data Set (MDS) version 3.0
Measure: Urinary Incontinence Time: January 2020 to July 2020 (cross-sectional)
Description: Patterns of sedentary behaviour (SB) with monitors (PAL Technologies, Scotland).
Measure: Patterns of sedentary behaviour Time: January 2020 to July 2020 (cross-sectional)
Description: Modified (Likert 5-point scale) Barthel Index, assessed every 6 months
Measure: Functional decline Time: January 2020 to January 2022 (longitudinal, follow-up)
Description: Minimum Data Set (MDS) version 3.0, assessed every 6 months
Measure: Continence decline Time: January 2020 to January 2022 (longitudinal, follow-up)
Description: Prospective register of falls (date, place and consequence/s)
Measure: Incidence of falls Time: January 2020 to January 2022 (longitudinal, follow-up)
Description: Prospective register of hospitalizations (date and cause)
Measure: Hospitalizations Time: January 2020 to January 2022 (longitudinal, follow-up)
Description: Prospective register of deaths (date and cause)
Measure: Mortality Time: January 2020 to January 2022 (longitudinal, follow-up)
Secondary Outcomes
Description: Sociodemographic variables (sex, age, civil status, education level, type of institution (public versus private / concerted) and time of residence in the institution.)
Measure: Sociodemographic variables Time: January 2020 to July 2020
Description: Number and proportion of participants with lower urinary tract symptoms with the International Prostate Symptoms Score and urinary infection for the last 30 days.
Measure: Lower urinary tract symptoms Time: January 2020 to July 2020
Description: Faecal incontinence according to Minimum Data Set version 3.0 (MDS 3.0)
Measure: Faecal incontinence Time: January 2020 to July 2020
Description: Diary
Measure: Intake of liquids and diuretic drinks Time: January 2020 to July 2020
Description: Dynamometer (2 trials per hand)
Measure: Handgrip strength Time: January 2020 to July 2020
Description: Short Physical Performance Battery (SPPB)
Measure: Physical performance Time: January 2020 to July 2020
Description: Rivermead Mobility Index
Measure: Mobility Time: January 2020 to July 2020
Description: Clinical Frailty Scale
Measure: Frailty Time: January 2020 to July 2020
Description: Modified (Likert 5-point scale) Barthel Index
Measure: Basic activities of daily living Time: January 2020 to July 2020
Description: What kind of physical activity programme, the frequency of the sessions weekly, the dose of exercise of each session, the duration of the whole session, who provides the session, where the session is performed and if the session is individually or in group).
Measure: Physical activity programs Time: January 2020 to July 2020
Description: What kind of programs are being applied to control and treat urinary and faecal incontinence in nursing homes
Measure: Incontinence programs Time: January 2020 to July 2020
Description: According to the Anatomical Therapeutic Chemical classification system and the Defined Daily Dose (ATC/DDD)
Measure: Medication intake Time: January 2020 to July 2020
Description: Number and proportion of participants with chronic diseases, delirium and pressure ulcers
Measure: Health conditions Time: January 2020 to July 2020
Description: European Quality of Life-5 Dimensions; final score for Spain ranges between 1 (full health) to -0.654 (worse outcome)
Measure: Quality of life Time: January 2020 to July 2020
Description: smoking and alcohol
Measure: Toxic habits Time: January 2020 to July 2020
Description: Pfeiffer Scale, with final score ranging from 0 (normal) to 10 (total cognitive impairment)
Measure: Cognitive status Time: January 2020 to July 2020
Description: 15-item Yesavage Geriatric Depression Scale, with final score ranging from 0 (normal) to 15 (severe depression)
Measure: Depressive symptoms Time: January 2020 to July 2020
Description: Hospital Anxiety and Depression Scale (HADS), with final score ranging from 0 (normal) to 21 (severe anxiety)
Measure: Anxiety Time: January 2020 to July 2020
Description: Using the NH register
Measure: Number births Time: January 2020 to July 2020
Description: Using the NH register
Measure: Type of births Time: January 2020 to July 2020
Description: During the last year, according to the NH register
Measure: Number of falls Time: January 2020 to July 2020
Description: Mini Nutritional Assessment Test, ranging from 0 (malnutrition) to 30 (normal)
Measure: Nutritional status Time: January 2020 to July 2020
Description: Amount of Vitamin D, albumin and pre-albumin, PCR (Protein C-Reactive) extracted from the routine analysis of the residents.
Measure: Biochemical evaluation Time: January 2020 to July 2020
Description: Percentage (%) of body fat, % of fat-free mass and % of body water assessed by a Tanita TBF-300 bioimpedance device
Measure: Body composition Time: January 2020 to July 2020
Description: Lubben Social Network Scale ranging from 0 to 30, with a higher score indicating more social engagement.
Measure: Social network Time: January 2020 to July 2020
Description: 6-item Gierveld Loneliness Scale ranging from 0 (not lonely) to 6
Measure: Loneliness Time: January 2020 to July 2020
Description: Date and result of diagnosis test/s for COVID-19 (PCR or serological antibody test)
Measure: COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)
Description: In the previous 6 months, the resident had symptoms compatible with COVID-19 (cough, fever and/or breathing difficulties) without COVID-19 diagnosis test confirmation
Measure: Suspected case of COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)
Description: Level of resident's frailty assessed with the Clinical Frailty Scale
Measure: Frailty Time: June 2020 to January 2022 (longitudinal, follow-up)
Description: Any change in the regular medication in the last 6 months (include the name of the med, dose and the duration of treatment)
Measure: Change in medication Time: June 2020 to January 2022 (longitudinal, follow-up)
HPO Nodes
HP:0000020: Urinary incontinence
Genes 164
CCL2 TYROBP PDGFRB PTCHD1 ACSL4 PANK2 SLC16A2 BAP1 AP5Z1 PSAP CLCN4 TERT PSAP ATXN10 SMO TTR TRPV4 SLC1A4 GBA2 CHMP2B PDGFB FTSJ1 GJC2 DNM2 USP27X PRDM8 BAP1 ATP13A2 UPF3B SACS HSPD1 CLCNKB HPSE2 COG5 GABRA1 WASHC5 VCP RAB39B HCFC1 PEX11B DNMT1 VANGL1 ZFYVE26 TIMM50 RETREG1 ARHGEF6 ARSA SQSTM1 PIK3CA HLA-DRB1 CACNA1H MYF6 ALG13 SPG7 SPG11 SLC9A6 CXORF56 AGTR2 PSAP AUH IQSEC2 DKK1 ALDH18A1 SBF1 PAK3 SMARCB1 HEXB VANGL2 ADNP JRK ARX MORC2 AKT1 SPAST ABCD1 HLA-DQB1 GABRB3 C19ORF12 ZNF41 COQ2 LRIG2 IL1RAPL1 RYR1 CACNA1G FRMPD4 GALC PDCD1 HSPD1 ZNF711 MTMR14 STUB1 DLG3 GABRG2 IFT57 HTRA1 SYP TRIO SLC20A2 HMBS KIF5A TIMM50 KCNC3 GDI1 FMR1 DMD MNX1 SLC9A7 CNKSR2 ALDH18A1 RPS6KA3 FA2H ATXN8 MID2 TBCD MORC2 ARSA CFAP43 RTN2 GBA2 BIN1 NOTCH3 FA2H IGHMBP2 TBXT DDHD2 NIPA1 GBA2 PDGFB ARSA KCND3 NIPA1 FUZ CAPN1 TSPAN7 SMARCE1 HS6ST2 CYP7B1 PSAP ATL1 MECP2 TRAF7 TBP FLVCR1 SCN9A USP9X AP5Z1 SLC2A1 BNC2 ATXN8OS SUFU NEXMIF FARS2 WASHC5 ALS2 RTN2 CACNA1G GBE1 MED12 SLC12A3 ARSA NF2 ZNF81 CPT1C HACE1 Protein Mutations 0
SNP 0
Primary Outcomes
Description: The presence of IU assessed by the Minimum Data Set (MDS) version 3.0
Measure: Urinary Incontinence Time: January 2020 to July 2020 (cross-sectional)Description: Patterns of sedentary behaviour (SB) with monitors (PAL Technologies, Scotland).
Measure: Patterns of sedentary behaviour Time: January 2020 to July 2020 (cross-sectional)Description: Modified (Likert 5-point scale) Barthel Index, assessed every 6 months
Measure: Functional decline Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Minimum Data Set (MDS) version 3.0, assessed every 6 months
Measure: Continence decline Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of falls (date, place and consequence/s)
Measure: Incidence of falls Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of hospitalizations (date and cause)
Measure: Hospitalizations Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of deaths (date and cause)
Measure: Mortality Time: January 2020 to January 2022 (longitudinal, follow-up)Secondary Outcomes
Description: Sociodemographic variables (sex, age, civil status, education level, type of institution (public versus private / concerted) and time of residence in the institution.)
Measure: Sociodemographic variables Time: January 2020 to July 2020Description: Number and proportion of participants with lower urinary tract symptoms with the International Prostate Symptoms Score and urinary infection for the last 30 days.
Measure: Lower urinary tract symptoms Time: January 2020 to July 2020Description: Faecal incontinence according to Minimum Data Set version 3.0 (MDS 3.0)
Measure: Faecal incontinence Time: January 2020 to July 2020Description: Diary
Measure: Intake of liquids and diuretic drinks Time: January 2020 to July 2020Description: Dynamometer (2 trials per hand)
Measure: Handgrip strength Time: January 2020 to July 2020Description: Short Physical Performance Battery (SPPB)
Measure: Physical performance Time: January 2020 to July 2020Description: Rivermead Mobility Index
Measure: Mobility Time: January 2020 to July 2020Description: Clinical Frailty Scale
Measure: Frailty Time: January 2020 to July 2020Description: Modified (Likert 5-point scale) Barthel Index
Measure: Basic activities of daily living Time: January 2020 to July 2020Description: What kind of physical activity programme, the frequency of the sessions weekly, the dose of exercise of each session, the duration of the whole session, who provides the session, where the session is performed and if the session is individually or in group).
Measure: Physical activity programs Time: January 2020 to July 2020Description: What kind of programs are being applied to control and treat urinary and faecal incontinence in nursing homes
Measure: Incontinence programs Time: January 2020 to July 2020Description: According to the Anatomical Therapeutic Chemical classification system and the Defined Daily Dose (ATC/DDD)
Measure: Medication intake Time: January 2020 to July 2020Description: Number and proportion of participants with chronic diseases, delirium and pressure ulcers
Measure: Health conditions Time: January 2020 to July 2020Description: European Quality of Life-5 Dimensions; final score for Spain ranges between 1 (full health) to -0.654 (worse outcome)
Measure: Quality of life Time: January 2020 to July 2020Description: smoking and alcohol
Measure: Toxic habits Time: January 2020 to July 2020Description: Pfeiffer Scale, with final score ranging from 0 (normal) to 10 (total cognitive impairment)
Measure: Cognitive status Time: January 2020 to July 2020Description: 15-item Yesavage Geriatric Depression Scale, with final score ranging from 0 (normal) to 15 (severe depression)
Measure: Depressive symptoms Time: January 2020 to July 2020Description: Hospital Anxiety and Depression Scale (HADS), with final score ranging from 0 (normal) to 21 (severe anxiety)
Measure: Anxiety Time: January 2020 to July 2020Description: Using the NH register
Measure: Number births Time: January 2020 to July 2020Description: Using the NH register
Measure: Type of births Time: January 2020 to July 2020Description: During the last year, according to the NH register
Measure: Number of falls Time: January 2020 to July 2020Description: Mini Nutritional Assessment Test, ranging from 0 (malnutrition) to 30 (normal)
Measure: Nutritional status Time: January 2020 to July 2020Description: Amount of Vitamin D, albumin and pre-albumin, PCR (Protein C-Reactive) extracted from the routine analysis of the residents.
Measure: Biochemical evaluation Time: January 2020 to July 2020Description: Percentage (%) of body fat, % of fat-free mass and % of body water assessed by a Tanita TBF-300 bioimpedance device
Measure: Body composition Time: January 2020 to July 2020Description: Lubben Social Network Scale ranging from 0 to 30, with a higher score indicating more social engagement.
Measure: Social network Time: January 2020 to July 2020Description: 6-item Gierveld Loneliness Scale ranging from 0 (not lonely) to 6
Measure: Loneliness Time: January 2020 to July 2020Description: Date and result of diagnosis test/s for COVID-19 (PCR or serological antibody test)
Measure: COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)Description: In the previous 6 months, the resident had symptoms compatible with COVID-19 (cough, fever and/or breathing difficulties) without COVID-19 diagnosis test confirmation
Measure: Suspected case of COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)Description: Level of resident's frailty assessed with the Clinical Frailty Scale
Measure: Frailty Time: June 2020 to January 2022 (longitudinal, follow-up)Description: Any change in the regular medication in the last 6 months (include the name of the med, dose and the duration of treatment)
Measure: Change in medication Time: June 2020 to January 2022 (longitudinal, follow-up)